Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2016 Jan 12;2016(1):CD005340.
doi: 10.1002/14651858.CD005340.pub4.

Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer

Kenneth Jaaback  1 , Nick Johnson, Theresa A Lawrie
Affiliations
Meta-Analysis

Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer

Kenneth Jaaback et al. Cochrane Database Syst Rev. .

Abstract

Background: Ovarian cancer tends to be chemosensitive and confine itself to the surface of the peritoneal cavity for much of its natural history. These features have made it an obvious target for intraperitoneal (IP) chemotherapy. Chemotherapy for ovarian cancer is usually given as an intravenous (IV) infusion repeatedly over five to eight cycles. Intraperitoneal chemotherapy is given by infusion of the chemotherapeutic agent directly into the peritoneal cavity. There are biological reasons why this might increase the anticancer effect and reduce some systemic adverse effects in comparison to IV therapy.

Objectives: To determine if adding a component of the chemotherapy regime into the peritoneal cavity affects overall survival, progression-free survival, quality of life (QOL) and toxicity in the primary treatment of epithelial ovarian cancer.

Search methods: We searched the Gynaecological Cancer Review Group's Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL) Issue 2, 2011, MEDLINE (1951 to May 2011) and EMBASE (1974 to May 2011). We updated these searches in February 2007, August 2010, May 2011 and September 2015. In addition, we handsearched and cascade searched the major gynaecological oncology journals up to May 2011.

Selection criteria: The analysis was restricted to randomised controlled trials (RCTs) assessing women with a new diagnosis of primary epithelial ovarian cancer, of any FIGO stage, following primary cytoreductive surgery. Standard IV chemotherapy was compared with chemotherapy that included a component of IP administration.

Data collection and analysis: We extracted data on overall survival, disease-free survival, adverse events and QOL and performed meta-analyses of hazard ratios (HR) for time-to-event variables and relative risks (RR) for dichotomous outcomes using RevMan software.

Main results: Nine randomised trials studied 2119 women receiving primary treatment for ovarian cancer. We considered six trials to be of high quality. Women were less likely to die if they received an IP component to chemotherapy (eight studies, 2026 women; HR = 0.81; 95% confidence interval (CI): 0.72 to 0.90). Intraperitoneal component chemotherapy prolonged the disease-free interval (five studies, 1311 women; HR = 0.78; 95% CI: 0.70 to 0.86). There was greater serious toxicity with regard to gastrointestinal effects, pain, fever and infection but less ototoxicity with the IP than the IV route.

Authors' conclusions: Intraperitoneal chemotherapy increases overall survival and progression-free survival from advanced ovarian cancer. The results of this meta-analysis provide the most reliable estimates of the relative survival benefits of IP over IV therapy and should be used as part of the decision making process. However, the potential for catheter related complications and toxicity needs to be considered when deciding on the most appropriate treatment for each individual woman. The optimal dose, timing and mechanism of administration cannot be addressed from this meta-analysis. This needs to be addressed in the next phase of clinical trials.

PubMed Disclaimer

Conflict of interest statement

There is no conflict of interest amongst the authors of this review.

Figures

1
1
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
2
2
Forest plot of comparison: 1 IP component therapy versus IV therapy, outcome: 1.1 Time to death.
3
3
Forest plot of comparison: 1 IP component therapy versus IV therapy, outcome: 1.3 Time to recurrence.
4
4
Forest plot of comparison: 1 IP component therapy versus IV therapy, outcome: 1.10 Adverse effects ‐ fever (G3‐4).
5
5
Forest plot of comparison: 1 IP component therapy versus IV therapy, outcome: 1.12 Adverse effects ‐ gastrointestinal (G3‐4).
6
6
Forest plot of comparison: 1 IP component therapy versus IV therapy, outcome: 1.13 Adverse effects ‐ infection (G3‐4).
7
7
Forest plot of comparison: 1 IP component therapy versus IV therapy, outcome: 1.16 Adverse effects ‐ pain (G3‐4).
1.1
1.1. Analysis
Comparison 1 IP component therapy versus IV therapy, Outcome 1 Time to death.
1.2
1.2. Analysis
Comparison 1 IP component therapy versus IV therapy, Outcome 2 Time to death restricted to same dose trials.
1.3
1.3. Analysis
Comparison 1 IP component therapy versus IV therapy, Outcome 3 Time to recurrence.
1.4
1.4. Analysis
Comparison 1 IP component therapy versus IV therapy, Outcome 4 Adverse effects ‐ anaemia (G3‐4).
1.5
1.5. Analysis
Comparison 1 IP component therapy versus IV therapy, Outcome 5 Adverse effects ‐ thrombocytopenia (G3‐4).
1.6
1.6. Analysis
Comparison 1 IP component therapy versus IV therapy, Outcome 6 Adverse effects ‐ leukopenia (G3‐4).
1.7
1.7. Analysis
Comparison 1 IP component therapy versus IV therapy, Outcome 7 Adverse effects ‐ renal (G3‐4).
1.8
1.8. Analysis
Comparison 1 IP component therapy versus IV therapy, Outcome 8 Adverse effects ‐ pulmonary (G3‐4).
1.9
1.9. Analysis
Comparison 1 IP component therapy versus IV therapy, Outcome 9 Adverse effects ‐ cardiovascular (G3‐4).
1.10
1.10. Analysis
Comparison 1 IP component therapy versus IV therapy, Outcome 10 Adverse effects ‐ fever (G3‐4).
1.11
1.11. Analysis
Comparison 1 IP component therapy versus IV therapy, Outcome 11 Adverse effects ‐ fatigue (G3‐4).
1.12
1.12. Analysis
Comparison 1 IP component therapy versus IV therapy, Outcome 12 Adverse effects ‐ gastrointestinal (G3‐4).
1.13
1.13. Analysis
Comparison 1 IP component therapy versus IV therapy, Outcome 13 Adverse effects ‐ infection (G3‐4).
1.14
1.14. Analysis
Comparison 1 IP component therapy versus IV therapy, Outcome 14 Adverse effects ‐ metabolic (G3‐4).
1.15
1.15. Analysis
Comparison 1 IP component therapy versus IV therapy, Outcome 15 Adverse effects ‐ neurologic (G3‐4).
1.16
1.16. Analysis
Comparison 1 IP component therapy versus IV therapy, Outcome 16 Adverse effects ‐ pain (G3‐4).
1.17
1.17. Analysis
Comparison 1 IP component therapy versus IV therapy, Outcome 17 Adverse effects ‐ hearing loss (G3‐4).
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Alberts 1996 {published data only}
    1. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. New England Journal of Medicine 1996;335(26):1950‐5. - PubMed
Gadducci 2000 {published data only}
    1. Gadducci A, Carnino F, Chiara S, Brunetti I, Tanganelli L, Romanini A, et al. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomised trial of the Gruppo Oncologico Nord‐Ovest. Gynecologic Oncology 2000;76(2):157‐62. - PubMed
GOG 172 {published and unpublished data}
    1. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. The New England Journal of Medicine 2006;354(1):34‐43. - PubMed
    1. Armstrong DK, Bundy BN, Baergen R, Lele SB, Copeland LJ, Walker, et al. Randomized phase III study of intravenous (IV) paclitaxel and cisplatin versus IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 172). Proceedings of the American Society of Clinical Oncology. 2002; Vol. 21:201a.
    1. Krivak TC, Tian C, Rose GS, Armstrong DK, Maxwell GL. A Gynecologic Oncology Group Study of serum CA‐125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: an analysis of patients enrolled in GOG 172. Gynecologic Oncology 2009;115(1):81‐5. - PMC - PubMed
    1. Lesnock J, Darcy K, Tian C, Gallion H, DeLoia J, Armstrong D, et al. Association between reduced BRCA1 expression and survival in patients with sporadic epithelial ovarian cancer treated with intraperitoneal versus intravenous cisplatin and paclitaxel: A Gynecologic Oncology Group study. Gynecologic Oncology 2010;116(Conference Publication: 3 Suppl.1):S3‐S4.
    1. Walker JL, Armstrong DK, Huang HQ, Fowler J, Webster K, Burger RA, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecologic Oncology 2006;100(1):27‐32. - PubMed
Kirmani 1994 {published data only}
    1. Kirmani S, Braly PS, McClay EF, Saltzstein SL, Plaxe SC, Kim S, et al. A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer. Gynecologic Oncology 1994;54(3):338‐44. - PubMed
Markman 2001 {published data only}
    1. Markman M, Bundy BN, Alberts DS, Fowler JM, Clark‐Pearson DL, Carson LF, et al. Phase III trial of standard‐dose intravenous cisplatin plus paclitaxel versus moderately high‐dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small‐volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. Journal of Clinical Oncology 2001;19(4):1001‐7. - PubMed
Polyzos 1999 {published data only}
    1. Polyzos A, Tsavaris N, Kosmas C, Giannikos L, Katsikas M, Kalahanis N, et al. A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer. Oncology 1999;56(4):291‐6. - PubMed
Yen 2001 {published data only}
    1. Yen MS, Juang CM, Lai CR, Chao GC, Ng HT, Yuan CC. Intraperitoneal cisplatin‐based chemotherapy vs. intravenous cisplatin‐based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer. International Journal of Gynecology and Obstetrics 2001;72(1):55‐60. - PubMed
Yen 2009 {published and unpublished data}
    1. Yen MS, Twu NF, Lai CR, Horng HC, Chao KC, Juang CM. Importance of delivered cycles and nomogram for intraperitoneal chemotherapy in ovarian cancer. Gynecologic Oncology 2009;114(3):415‐9. - PubMed
Zylberberg 1986 {published data only}
    1. Zylberberg B, Ravina JH, Salat‐Baroux J, Dormont D, Lipp B, Guillet JL. Polychemotherapy of ovarian cancer via combined intravenous and intraperitoneal routes. Technic and preliminary results [Polychimiotherapie des cancers de l'ovaire par voie mixte intraveineuse et intraperitoneale. Technique et resultats preliminaires]. Journal de Gynécologie Obstétrique et Biologie de la Reproduction 1986;15(5):671‐6. - PubMed

References to studies excluded from this review

Piccart 2003 {published data only}
    1. Piccart MJ, Floquet A, Scarfone G, Willemse PH, Emerich J, Vergote I, et al. Intraperitoneal cisplatin versus no further treatment: 8‐year results of EORTC 55875, a randomised phase III study in ovarian cancer patients with a pathologically complete remission after platinum‐based intravenous chemotherapy. International Journal of Gynecological Cancer 2003;13 Suppl 2:196‐203. - PubMed

References to ongoing studies

GOG 0252 {unpublished data only}
    1. GOG‐0252. Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer. ClinicalTrials.gov Identifier: NCT00951496.
GOTIC‐001/JGOG‐3019 {published and unpublished data}
    1. Aotani E, Kukino S, Nonaka M, Nagao S, Fujiwara K. First attempt of large phase III oncology trial using Japanese new trial evaluation system, the evaluation system of investigational medical care. Japanese Pharmacology and Therapeutics 2010;38(Suppl.1):S59‐S64.
    1. Fujiwara K, Aotani E, Hamano T, Nagao S, Yoshikawa H, Sugiyama T, et al. A randomized phase II/III trial of 3 weekly intraperitoneal versus intravenous carboplatin in combination with intravenous weekly dose‐dense paclitaxel for newly diagnosed ovarian, fallopian tube and primary peritoneal cancer. Japanese Journal of Clinical Oncology 2011;41(2):278‐82. - PubMed
Hyperthermic IP therapy {unpublished data only}
    1. Secondary debulking surgery +/‐ hyperthermic intraperitoneal chemotherapy in stage III ovarian cancer. http://www.bioportfolio.com/resources/trial/102235/Secondary‐Debulking‐S....
    1. Secondary debulking surgery +/‐ hyperthermic intraperitoneal chemotherapy in stage III ovarian cancer. http://www.cancer.gov/clinicaltrials/search/view?cdrid=533399&versio....
NCIC CTG OV.21 {published and unpublished data}
    1. Mackay HJ, Provencheur D, Heywood M, Tu D, Eisenhauer EA, Oza AM. Phase II/III study of intraperitoneal chemotherapy after neoadjuvant chemotherapy for ovarian cancer: NCIC CTG OV.21. Current Oncology 2011;18(2):84‐90. [NCT00993655] - PMC - PubMed

Additional references

ACS 2005 [Computer program]
    1. American Cancer Society. Detailed Guide: Ovarian Cancer. What are the key statistics about ovarian cancer?. American Cancer Society, 2005.
Armstrong 2006
    1. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. The New England Journal of Medicine 2006;354(1):34‐43. - PubMed
Bristow 2002
    1. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta‐analysis. Journal of Clinical Oncology 2002;20:1248‐59. - PubMed
Burghardt 1991
    1. Burghardt E, Girardi F, Lahousen M, Tamussino K, Stettner H. Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecologic Oncology 1991;40 (2):103‐6. - PubMed
Chi 2010
    1. Chi D, Dao F, Ferguson S, Sabbatini P, Hensley M, Konner J, et al. Analysis of progression‐free survival, tolerability and toxicity in patients with stage III ovarian, tubal and peritoneal carcinoma treated with an outpatient regimen of primary intravenous/ intraperitoneal paclitaxel and intraperitoneal cisplatin. Gynecologic Oncology 2010;Conference Publication: 116(3 Suppl 1):S123.
Deraco 2011
    1. Deraco M, Kusamura S, Virzì S, Puccio F, Macrì A, Famulari C, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: Multi‐institutional phase‐II trial. Gynecologic Oncology 2011;122(2):215‐20. - PubMed
du Bois 2003
    1. du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, et al. A randomised clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first‐line treatment of ovarian cancer. Journal of the National Cancer Institute 2003;95(17):1320‐9. - PubMed
Fujiwara 2008
    1. Fujiwara 2008. Can carboplatin replace cisplatin for intraperitoneal use?. International Journal of Gynecological Cancer 2008;18(Suppl 1):29‐32. - PubMed
Fujiwara 2009
    1. Fujiwara K, Nagao S, Kigawa J, Noma J, Akamatsu N, Miyagi Y, et al. Phase II study of intraperitoneal carboplatin with intravenous paclitaxel in patients with suboptimal residual epithelial ovarian or primary peritoneal cancer: A Sankai Gynecology Cancer Study Group Study. International Journal of Gynecological Cancer 19;5:834‐7. - PubMed
Fujiwara 2012
    1. Fujiwara K. Three ongoing intraperitoneal chemotherapy trials in ovarian cancer. Journal of Gynecologic Oncology 2012;23(2):75‐7. - PMC - PubMed
Gray 2010
    1. Gray HJ, Shah CA, Swensen RE, Tamimi HK, Goff BA. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer. Gynecologic Oncology 2010;116(3):340‐4. - PubMed
Higgins 2009
    1. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from www.cochrane‐handbook.org.
Howell 1982
    1. Howell SB, Pfeifle CL, Wung WE, Olshen RA, Lucas WE, Yon JL, et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Annals of Internal Medicine 1982;97:845‐51. - PubMed
Jones 1978
    1. Jones RB, Myers CE, Guarino AM, Dedrick RL, Hubbard SM, DeVita VT. High volume intraperitoneal chemotherapy ("belly bath") for ovarian cancer. Pharmacologic basis and early results. Cancer Chemotherapy and Pharmacology 1978;1(3):161‐6. - PubMed
Katsumata 2009
    1. Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, et al. Dose‐dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open‐label, randomised controlled trial. Lancet 2009;374:1331‐8. - PubMed
Lopez 1985
    1. Lopez JA, Krikorian JG, Reich SD, Smyth RD, Lee FH, Issell BF. Clinical pharmacology of intraperitoneal cisplatin. Gynecologic Oncology 1985;20(1):1‐9. - PubMed
Los 1990
    1. Los G, Mutsaers PH, Lenglet WJ, Baldew GS, McVie JG. Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemotherapy and Pharmacology 1990;25(6):389‐94. - PubMed
Makhija 2001
    1. Makhija S, Leitao M, Sabbatini P, Bellin N, Almadrones L, Leon L, et al. Complications associated with intraperitoneal chemotherapy catheters. Gynecologic Oncology 2001;81(1):77‐81. - PubMed
Markman 1999
    1. Markman M. IP chemotherapy. Critical Reviews in Oncology/ Hematology 1999;31:239‐46. - PubMed
Ozols 2003
    1. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke‐Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. Journal of Clinical Oncology 2003;21(17):3194‐200. - PubMed
Parmar 1998
    1. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815‐34. - PubMed
RevMan 2008 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
Weisberger 1955
    1. Weisberger AS, Levine B, Storaasli JP. Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. JAMA 1955;159(18):1704‐7. - PubMed
Wenzel 2004
    1. Wenzel LB, Huang H, Armstrong D, Walker J, Cella D. Quality of life (QOL) results of a randomised study of intravenous (IV) paclitaxel and cisplatin vs IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): A Gynecologic Oncology Group trial. Journal of Clinical Oncology 2004;22(14S):5026.
Wenzel 2007
    1. Wenzel LB, Huang HQ, Armstrong DK, Walker JL, Cella D, and Gynecologic Oncology Group. Health‐related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology 2007;25(4):437‐43. - PubMed
Zeimet 2009
    1. Zeimet AG, Reimer D, Radl AC, Reinthaller A, Schauer C, Petru E, et al. Review: Pros and cons of intraperitoneal chemotherapy in the treatment of epithelial ovarian cancer. Anticancer Research 2009;29(7):2803‐8. - PubMed
Zhao 2013
    1. Zhao H, Du N, Fu Y, Wang H, Fan Z. Clinical study of intraperitoneal injection bevacizumab (BV) combined with intraperitoneal hyperthermic perfusion chemotherapy (CT) in treatment of malignant ascites of ovarian cancer (OC). Journal of Clinical Oncology. Annual Meeting of the American Society of Clinical Oncology, ASCO Chicago, IL United States. 2013; Vol. 31:15 Suppl. 1.

References to other published versions of this review

Jaaback 2007
    1. Jaaback K, Johnson N. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD005340.pub2] - DOI - PMC - PubMed
Jaaback 2011
    1. Jaaback K, Johnson N, Lawrie TA. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2011, Issue 11. [DOI: 10.1002/14651858.CD005340.pub3] - DOI - PMC - PubMed

MeSH terms

Substances